US Pharm. 2013;38(3):7.
Phoenix, AZ—Taking regular doses of selumetinib has resulted
in tumor stabilization or shrinkage in many women with low-grade serous
carcinoma of the ovary or peritoneum, according to researchers. In what
is considered a potentially important breakthrough, the compound targets
a mutation in the mitogen-activated protein kinase pathway in patients
with low-grade serous carcinoma, permitting treatment of previously
chemoresistant tumors. Of 52 participants in the phase II trial, eight
had a measurable decrease in tumor size, seven showed a partial
response, and 34 experienced tumor stabilization. Phase III of this
trial, which is scheduled to begin shortly, will be the definitive test
before the treatment is made available to the general population.
To comment on this article, contact email@example.com.